Tuberculosis remains one of medicine's most stubborn unfinished battles, and this comprehensive GBD 2023 analysis arrives at a critical inflection point — just as global health funding cuts threaten to unravel decades of hard-won progress. Understanding where the epidemic stands before these disruptions take hold is essential for any rational public health strategy going forward.
The analysis covers 204 countries and territories from 1990 to 2023, quantifying TB mortality through the Cause of Death Ensemble modelling platform, drawing on vital registration data, surveillance systems, verbal autopsies, and minimally invasive tissue sampling. Morbidity estimates — incidence, prevalence, and mortality stratified by age and sex — were generated simultaneously using DisMod-MR 2.1. Crucially, the team applied a population attributable fraction framework to disaggregate the burden by HIV co-infection status and drug-resistance profile, including multidrug-resistant TB (MDR-TB). Disability-adjusted life-years (DALYs) were computed as the combined sum of years of life lost and years lived with disability. Risk factor attribution extended to alcohol use, smoking, and elevated fasting plasma glucose — metabolic and behavioral exposures increasingly recognized as TB vulnerability amplifiers.
This is precisely the kind of foundational epidemiological infrastructure that makes targeted intervention possible, and the GBD methodology is among the most rigorous available for cross-national comparison. However, the quality of underlying data varies enormously across the 204 territories assessed — vital registration is strong in high-income settings but sparse across much of sub-Saharan Africa and South Asia, where TB burden is heaviest. The WHO End TB Strategy's targets — a 95% mortality reduction and 90% incidence reduction by 2035 against a 2015 baseline — appear increasingly precarious given current funding trajectories. The explicit incorporation of MDR-TB and HIV co-infection stratification adds genuine value, as these subgroups carry disproportionate mortality risk and require distinct clinical and programmatic responses. Overall, this analysis is confirmatory in methodology but potentially paradigm-shaping in its policy timing — arriving precisely when evidence-based advocacy is most urgently needed.